2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow Adverse Event: new trials by email Literature Review of Adverse Event trials Research Report on Adverse Event
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) Acalabrutinib 2x100 MG Oral Capsule + alloSCT - Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease | Phase 2 | Completed | Polish Lymphoma Research Group | 29 | 2019-08-19 | 2025-01-16 |
| LIFEMEL Efficacy in Preventing Haematopoietic Toxicity in Patients Treated With Chemotherapy Lifemel - Neutropenia, Adverse Event | Phase 2 | Completed | VitalMel | 39 | 2013-11-11 | 2020-09-24 |
Bronchiolitis Obliterans Syndrome (1) · Leukemia, B-Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Mantle-Cell (1) · Neoplasm, Residual (1) · Neutropenia (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Agranulocytosis (1) · Bronchial Diseases (1) · Bronchiolitis (1) · Bronchiolitis Obliterans (1) · Bronchitis (1) · Chronic Disease (1) · Cytopenia (1) · Disease Attributes (1) · Graft vs Host Disease (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, Lymphoid (1)
Polish Lymphoma Research Group (1) · VitalMel (1)
Poland (1)